Latest Protein Potential LLC Stories

ROCKVILLE, Md., Sept. 25, 2012 /PRNewswire-USNewswire/ -- Protein Potential, LLC was awarded three Phase I Small Business Innovation Research (SBIR) grants from the National Institutes of Health (NIH) to develop a malaria vaccine that protects against Plasmodium falciparum, the malaria parasite responsible for more than 95% of malaria associated deaths worldwide. The vaccine will target three different stages of the parasite life cycle, thereby preventing infection, disease, and...

ROCKVILLE, Md., April 19 /PRNewswire/ -- Protein Potential LLC has received support from the National Institute of Allergy and Infectious Diseases (NIAID) of the NIH in the form of a Phase II Small Business Innovation Research (SBIR) Grant. The three-year award totaling approximately $3 million will support translational research to develop a vaccine for the prevention of malaria caused by the parasite Plasmodium vivax. Approximately 40% of the world's population is at risk from malaria...